Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 271 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Failure Acute Clear all
Completed Not applicable Interventional

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

NCT04019314
View directory record Official record
Conditions
Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions
Blood Collection, Blood Volume Analysis
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jul 22, 2026, 4:45 AM EDT
Recruiting Phase 3 Interventional

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve System, furosemide infusion
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
37
States / cities
Irvine, California • La Jolla, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics

NCT04877652
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Standard of care
Other
Lead sponsor
Revamp Medical Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 22, 2026, 4:45 AM EDT
Completed Not applicable Interventional

Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department

NCT01193998
View directory record Official record
Conditions
Dyspnea, Acute Heart Failure, Shortness of Breath
Interventions
Treatment as per model probability, Treatment as per usual care
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated Phase 4 Interventional

Dopamine in Acute Decompensated Heart Failure II

NCT01060293
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
High-dose furosemide, Low-dose furosemide, Low-dose furosemide combined with low-dose dopamine
Drug
Lead sponsor
Larissa University Hospital
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Jul 22, 2026, 4:45 AM EDT
Enrolling by invitation Phase 2 Interventional

Ketones in Heart Failure With Reduced Ejection Fraction

NCT06195982
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
ketone ester, placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jul 22, 2026, 4:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

NCT00559650
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Placebo, Cinaciguat (BAY58-2667)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 22, 2026, 4:45 AM EDT
Recruiting No phase listed Observational

Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure

NCT06253104
View directory record Official record
Conditions
Heart Failure, Muscle Atrophy, Skeletal Muscle Atrophy, Cardiogenic Shock
Interventions
BodyMetrix Body Composition Ultrasound
Diagnostic Test
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 22, 2026, 4:45 AM EDT
Completed Not applicable Interventional

An Observational Study of the Functional Capacity of Heart Failure

NCT02350114
View directory record Official record
Conditions
Acute Heart Failure
Interventions
6 Minute Walk Test
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Jul 22, 2026, 4:45 AM EDT
Completed Phase 1Phase 2 Interventional

BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.

NCT00252200
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
Neseritide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Jul 22, 2026, 4:45 AM EDT
Withdrawn Not applicable Interventional

Study of Percutaneous Renal Artery Intervention for Patient With Heart Failure

NCT01403714
View directory record Official record
Conditions
Heart Failure
Interventions
Renal Artery Stenting
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615
View directory record Official record
Conditions
Acute Heart Failure With Reduced Ejection Fraction
Interventions
APD418, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jul 22, 2026, 4:45 AM EDT
Completed Phase 3 Interventional

Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

NCT00348504
View directory record Official record
Conditions
Acute Heart Failure
Interventions
levosimendan, dobutamine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jul 22, 2026, 4:45 AM EDT
Active, not recruiting Phase 1 Interventional

Effects of Acute and Chronic Empagliflozin Heart Failure

NCT05553938
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

NCT00744341
View directory record Official record
Conditions
Acute Decompensated Heart Failure; Renal Dysfunction
Interventions
SLV320, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Alameda, California • Banning, California • Inglewood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Jul 22, 2026, 4:45 AM EDT
Terminated No phase listed Observational

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

NCT03935178
View directory record Official record
Conditions
Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions
Measuring Right Ventricular Size and Function
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 22, 2026, 4:45 AM EDT
Not yet recruiting Not applicable Interventional

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

NCT07634419
View directory record Official record
Conditions
Critical Illness, Heart Failure, Sepsis, Ards, Pneumonia, Trauma Injury
Interventions
Lift mobile mindfulness, Enlighten Recovery education program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure

NCT04999995
View directory record Official record
Conditions
Heart Failure, Dyspnea; Cardiac
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 22, 2026, 4:45 AM EDT
Withdrawn Phase 1 Interventional

Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study

NCT03924102
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jul 22, 2026, 4:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

NCT05713266
View directory record Official record
Conditions
COVID-19, Long COVID
Interventions
MouthLabTM
Device
Lead sponsor
Edith Nourse Rogers Memorial Veterans Hospital
Federal
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 22, 2026, 4:45 AM EDT